Doer Biologics

Zhejiang Doer Biologics Co., Ltd., located in Qiantang New District, Hangzhou City, Zhejiang Province, was established on April 1, 2014. It is an innovation-driven biopharmaceutical research and development company. The company focuses on developing multi-specific innovative protein drugs based on multi-domain structures to meet unmet clinical needs in the fields of metabolic diseases, cancer, ophthalmology, and more. Doer Biologics is one of the few companies in China with proprietary intellectual property technology platforms dedicated to the development of innovative biopharmaceuticals. The company owns several unique protein engineering platform technologies, including xLONGylation® -- a recombinant PEG-like modification (rPEG) platform for extending the half-life of proteins, MultipleBody® -- a multi-target technology platform, HTS-VHHBody -- a high-throughput discovery and modification platform for single-domain antibodies, and AccuBody® -- a precision oncology treatment technology platform. Based on these technology platforms, the company has developed multiple innovative multi-specific protein drugs based on multi-domain structures. The core research team of Doer Biologics consists of young but experienced experts in the biopharmaceutical field. Currently, the company has divisions such as New Drug Discovery, Process Development, Physicochemical Analysis, Bioanalysis, Business Development and Collaboration, and Intellectual Property.